TITLE

GSK Names New Chairman

PUB. DATE
March 2006
SOURCE
Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p174
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces the appointment of Moncef Slaoui as chairman of research and development at GlaxoSmithKline effective June 1, 2006. Slaoui will report to Chief Executive Officer Jean-Pierre Garnier. Slaoui succeeds Tadataka Yamada who will retire from the company to become executive director of the global health program at the Bill and Melinda Gates Foundation.
ACCESSION #
20227936

 

Related Articles

  • Landmark green light for Mosquirix malaria vaccine. Morrison, Chris // Nature Biotechnology;Oct2015, Vol. 33 Issue 10, p1015 

    The article reports that Pharmaceutical firm GlaxoSmithKline has received approval from the European Medicines Agency (EMA) to launch its Mosquirix malaria vaccine for the use by children in high transmission areas. It states that the final phase 3 trial results for Mosquirix were published by...

  • Fat-cat salaries are the best way to get the cream. Pitcher, George // Marketing Week;5/29/2003, Vol. 26 Issue 22, p27 

    Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay...

  • GSK improves on Theravance pact. Tyler, Alan // European Chemical News;4/5/2004, Vol. 80 Issue 2094, p23 

    Reports that GlaxoSmithKline (GSK) has boosted its stake in Theravance, a privately-held pharmaceutical company specialising in a multivalent small molecule discovery approach. Terms of the alliance agreement between GSK and Theravance; Benefit of the alliance to Theravance; Comments from...

  • Moncef Slaoui.  // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p452 

    An interview with Moncef Slaoui, chairman of vaccines at the pharmaceutical company GlaxoSmithKline is presented. He talks about the company's rationale for swapping its oncology for Novartis' vaccine business, which he says is part of the company's medium and long term strategy. He discusses...

  • News in brief.  // Nature Reviews Drug Discovery;Jul2008, Vol. 7 Issue 7, p550 

    The article offers world news briefs related to medicine. Seven new biomarkers of drug-induced kidney injury have gained approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Denmark-based Santaris Pharma A/S has announced its Phase I clinical trial...

  • Good Science And The Marketplace For Drugs: A Conversation With Jean-Pierre Garnier. Iglehart, John K. // Health Affairs;Jul/Aug2003, Vol. 22 Issue 4, p119 

    Interviews Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline. Expansion of the scope of Medicare's prescription drug benefits; GlaxoSmithKline's drug research and development activities; Challenges posed by the generic market; Future of drug development.

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune International (Europe);3/21/2005, Vol. 151 Issue 5, p20 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • GSK makes strides in R&D.  // European Chemical News;12/8/2003, Vol. 79 Issue 2080, p28 

    Reports on the research and development (R&D) achievements of GlaxoSmithKline (GSK) presented by chief executive officer Jean-Pierre Garnier to investors in December 2003. Number of projects in clinical development; Number of chemical entities developed by GSK; R&D innovation launched by the...

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune;3/21/2005, Vol. 151 Issue 6, p38 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics